// App-Quantinova.ai

P261 : Burden of bowel urgency across specific treatment groups among Ulcerative Colitis patients – real world global study analyses

Researchers

Presenter

  • Atreya, R

Principal Investigators

  • Redondo, I

  • Hill, J

  • Streit, P

  • Hartz, S

  • Knight, H

  • Barlow, S

  • Hennessy, F

  • Hunter, T

Medical Centers

  • University Hospital Erlangen- Friedrich-Alexander-University Erlangen-Nurnberg, Medical Department , Erlangen, Germany

  • Eli Lilly and Company, International Medical, Lisbon, Portugal

  • Eli Lilly and Company, International PRA, Bracknell, United Kingdom

  • Eli Lilly and Company, Global PRA, Vernier, Switzerland

  • Eli Lilly and Company, Global Patient Outcomes Real World Evidence, Bracknell, United Kingdom

  • Adelphi Real World, Real World Evidence, Bollington, United Kingdom

  • Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, United States of America

Locations

  • Germany

  • Portugal

  • United Kingdom

  • Switzerland

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Genetic Disorder

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

Biomarkers

  • Janus kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved